drugset
drugset / Trial / NCT04223960

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

NCT04223960 ↗

Phase 1 Completed 184 enrolled EA Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindOther

Summary

The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.

Timeline

Start
2020-01-09
Primary completion
2023-08-06
Completion
2023-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject EA1080 Unknown — Oral

Indications

No indication recorded.